Encepheal Therapeutics YC 申请

Summer 2019Inactive

Encepheal Therapeutics 在 Summer 2019 批次的 Y Combinator 中作为一家 Healthcare 公司进行过。以下是：公司做什么、谁创立了它，以及其 YC 申请，按照真实 YC 表格逐题重建。

YC 批次: Summer 2019
行业: HealthcareTherapeutics
团队规模: 3
状态: Inactive
已发布: 2019

创始人

Aaron LazarusFounder
Omeed RahimiFounder

Encepheal Therapeutics 做什么

EncepHeal is developing medications to treat substance abuse. Our first product is a small molecule therapeutic for stimulants like cocaine and methamphetamine, of which there are no FDA approved treatments. Our small molecule technology are atypical inhibitors of the dopamine transporter. Cocaine itself is an inhibitor of the same transporter. Directly reducing craving or positive reinforcement is a successful treatment strategy for addiction. Methadone or buprenorphine (Suboxone) are key examples of this for opioid use disorder. However, these types of medications can be addictive themselves. This has been a major hurdle for medication development for cocaine addiction and has led to many leaders in the addiction space to abandon the dopamine transporter as a target. At EncepHeal, we believe that the dopamine transporter should not be abandoned and instead focusing on fixing the abuse liability problem. Therefore with our partners at the National Institutes of Health, we have shown that these new, allosteric modulators at the dopamine transporter do not display addictive tendencies in animal models. They are also effective at curbing cocaine addiction. Our management team has two co-founders, Omeed Rahimi and Aaron Lazarus, as well as an experienced addiction pharmacologist as their research officer. The team has an advisory board with entrepreneurial and addiction drug development experience as well as expert partners at the National Institute on Drug Abuse, a subset of the NIH, and Wake Forest. Our team has had success in raising non-dilutive funding and has expertise with SBIR/STTR grants. We are looking for help in better connecting with the biotech/pharmaceutical industry.

Encepheal Therapeutics 的 YC 申请，重建版

Y Combinator 申请

Encepheal Therapeutics，Summer 2019 期。来自公开数据的真实申请问题解答。

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Encepheal Therapeutics

Describe what your company does in 50 characters or less.

Medications to treat substance abuse

What is your company going to make? Please describe your product and what it does or will do.

We're developing small molecule drugs that target the dopamine transporter to treat stimulant addiction, starting with cocaine and methamphetamine. Our compounds modulate the dopamine transporter allosterically to reduce addictive cravings without the addictive properties of current dopamine transporter inhibitors.

Where do you live now, and where would the company be based after YC?

We currently live and work in Winston-Salem, NC, and the company is based there. After YC, we plan to maintain our base in Winston-Salem due to our partnerships and existing infrastructure.

Explain your decision regarding location.

We chose Winston-Salem because we have strong research collaborations with the National Institutes of Health and Wake Forest, which are local. This proximity helps us advance our drug development efficiently.

21 更多回答在完整申请中

Founders, Progress, Idea, Equity, Curious, Batch Preference 包含在完整版中。创建免费账户即可在 YC Insights 中打开，紧邻每个其他 YC 批次。

查看完整申请

常见问题解答

这是 Encepheal Therapeutics 的真实 YC 申请吗？

不是。Y Combinator 对提交的申请保密。这是重建版：使用 Encepheal Therapeutics 的公开数据（发布笔记、创始人背景、产品描述）回答真实的 YC 表格问题。它展示了像 Encepheal Therapeutics 这样的公司会如何向 YC 自我介绍，而不是他们提交的文本。

Encepheal Therapeutics 是哪个 YC 批次的？

Encepheal Therapeutics 是 Y Combinator Summer 2019 批次的成员。

谁创立了 Encepheal Therapeutics？

Encepheal Therapeutics 由 Aaron Lazarus, Omeed Rahimi 创立。

Encepheal Therapeutics 做什么？

EncepHeal develops medications to treat substance abuse, starting…

如何阅读完整的重建申请？

创建免费的 Round Funded 账户。YC Insights 中包含 Encepheal Therapeutics 的完整 26 个问题的版本，以及其他所有 YC 批次的公司信息。